Get access to Genentech information and resources for stories in development. Find recent and archived press releases.
On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.
On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.
On March 28, the FDA approved the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis.
On December 6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.
On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).
On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.
On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.
On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.
On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.
On November 10, 2015, the FDA approved a new medicine for the treatment of advanced melanoma.
On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).
On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.
On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.
On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.
On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA’s Breakthrough Therapy Designation.
Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.
On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.
Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.